1997 CMS Letter to Mylan (MYL) Shows Evidence of EpiPen Medicaid Rebate - Evecore ISI's Raffat

September 7, 2016 11:24 AM EDT
Get Alerts MYL Hot Sheet
Price: $37.02 -1.57%

Rating Summary:
    11 Buy, 12 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade MYL Now!
Join SI Premium – FREE

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

Evecore ISI Mylan (NASDAQ: MYL) analyst Umer Raffat notes that while there has been considerable investor debate around whether Mylan misclassified Epipen to Medicaid, they have uncovered a letter in the public domain from CMS to Mylan from back in 1997.

In this letter, CMS recommended to Mylan that "it is entirely fitting and proper" for Mylan report Epipen as "non-innovator" to Drug Rebate Program.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot Comments, Short Sales, Trader Talk

Related Entities

Umer Raffat

Add Your Comment